Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cisplatin + Gemcitabine + MRTX1719 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
| Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
| MRTX1719 | MRTX-1719|MRTX 1719|BMS 986504|BMS986504|BMS-986504|BMS986504|Navlimetostat | PRMT5 Inhibitor 21 | MRTX1719 inhibits the PRMT5-MTA complex, which potentially results in reduced tumor growth (PMID: 35041419). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07532902 | Phase I | Cisplatin + Gemcitabine + MRTX1719 Ipilimumab + MRTX1719 + Nivolumab Carboplatin + Gemcitabine + MRTX1719 Fluorouracil + Leucovorin + MRTX1719 + Nivolumab + Oxaliplatin | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | Recruiting | USA | 0 |